LIFECORE BIOMEDICAL, INC. \DE\LFCREarnings & Financial Report
LIFECORE BIOMEDICAL, INC. is a biomedical firm focused on developing and manufacturing high-quality hyaluronic acid-based biomaterials. It operates three core segments: medical application products, pharmaceutical solutions, and personal care ingredients, with main markets spanning North America, Europe and the Asia-Pacific, supplying to leading medical device, pharmaceutical and cosmetic brand partners.
Revenue
$35.7M
Gross Profit
$11.9M
Operating Profit
$-895.0K
Net Profit
$15.6M
Gross Margin
33.3%
Operating Margin
-2.5%
Net Margin
43.8%
YoY Growth
34.5%
EPS
$0.42
LIFECORE BIOMEDICAL, INC. \DE\ Q3 FY2024 Financial Summary
LIFECORE BIOMEDICAL, INC. \DE\ reported revenue of $35.7M (up 34.5% YoY) for Q3 FY2024, with a net profit of $15.6M (up 142.8% YoY) (43.8% margin). Cost of goods sold was $23.8M, operating expenses totaled $12.8M.
Key Financial Metrics
| Total Revenue | $35.7M |
|---|---|
| Net Profit | $15.6M |
| Gross Margin | 33.3% |
| Operating Margin | -2.5% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
LIFECORE BIOMEDICAL, INC. \DE\ Q3 FY2024 revenue of $35.7M breaks down across 2 segments, led by Contract Development And Manufacturing Organization at $22.3M (62.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Contract Development And Manufacturing Organization | $22.3M | 62.5% |
| Fermentation | $13.4M | 37.5% |
LIFECORE BIOMEDICAL, INC. \DE\ Annual Revenue by Year
LIFECORE BIOMEDICAL, INC. \DE\ annual revenue history includes year-by-year totals (for example, 2023 revenue was $103.3M).
| Year | Annual Revenue |
|---|---|
| 2023 | $103.3M |
| 2022 | $111.3M |
LIFECORE BIOMEDICAL, INC. \DE\ Quarterly Revenue & Net Profit History
LIFECORE BIOMEDICAL, INC. \DE\ results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $31.1M | -4.5% | $-10.0M | -32.1% |
| Q3 FY2025 | $35.2M | -1.5% | $-14.8M | -42.0% |
| Q2 FY2025 | $32.6M | +8.0% | $-6.6M | -20.2% |
| Q1 FY2025 | $24.7M | +0.7% | $-16.2M | -65.7% |
| Q3 FY2024 | $35.7M | +34.5% | $15.6M | 43.8% |
| Q2 FY2024 | $30.1M | +37.9% | $14.2M | 47.2% |
| Q1 FY2024 | $24.5M | +3.4% | $-10.8M | -43.9% |
| Q4 FY2023 | $31.1M | +10.8% | $-39.3M | -126.1% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $31.1M | $24.5M | $30.1M | $35.7M | $24.7M | $32.6M | $35.2M | $31.1M |
| YoY Growth | 10.8% | 3.4% | 37.9% | 34.5% | 0.7% | 8.0% | -1.5% | -4.5% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $253.5M | $245.6M | $245.8M | $246.2M | $246.8M | $255.4M | $237.7M | $235.2M |
| Liabilities | $218.5M | $219.1M | $203.5M | $186.8M | $207.3M | $195.6M | $190.3M | $198.4M |
| Equity | N/A | $-13.6M | $1.4M | $17.7M | $-3.9M | $15.4M | $2.2M | $-10.5M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.3M | $-8.3M | $1.3M | $-1.4M | $-613000 | $-6.1M | $1.2M | $1.8M |